Supply risk analysis: applying system dynamics to the Colombian healthcare sector

Análisis del riesgo de aprovisionamiento: caso aplicado al sector salud colombiano, utilizando la dinámica de sistemas

J. P. Zamora Aguas1, W. A. Adarme2, M. D. Arango Serna3

ABSTRACT

This paper addresses supply risk in the oncological medicine supply chain (SC) in Colombia. A system dynamics model was developed for assessing supply risk impact on SC operation and performance. The costs of risk and logistics operation were evaluated in current conditions and in a risk mitigation scenario. The model was based on a systematic analysis of supply networks, mainly concerning the reduction of overall SC costs and improving service, quality and opportunity performance index. This article has resulted from research into SC risk management (SCRM) carried out by the Universidad Nacional de Colombia’s SEPRO research group.

Keywords: supply risk, supply chain, oncology drugs, system dynamics.

RESUMEN

En este artículo se aborda la problemática del riesgo de aprovisionamiento en la cadena de suministro (CS) de medicamentos oncológicos en Colombia. Se desarrolla un modelo de dinámica de sistemas para evaluar el impacto del riesgo de aprovisionamiento, sobre las condiciones de operación y desempeño de la CS. Se valoran los costos del riesgo y de la operación logística en las condiciones actuales y en un escenario con mitigación del riesgo. Las contribuciones del modelo se basan en el análisis sistémico de las redes de suministro, principalmente, en la reducción de los costos globales de la cadena y en la mejora de los índices de desempeño en oportunidad, calidad y servicio. Este artículo es el resultado de la investigación de gestión del riesgo en la cadena de suministro (SCRM – Supply Chain Risk Management), realizada por el grupo de investigación SEPRO de la Universidad Nacional de Colombia.

Palabras clave: riesgo de aprovisionamiento, cadena de suministro, medicamentos oncológicos y dinámica de sistemas.

Received: April 11th 2013
Accepted: October 7th 2013

Introduction

Supply chain (SC) risk refers to the possibility of shortages or disruptions occurring regarding materials, product and service flows in the SC. This implies the possibility and effect of a mismatch between supply and demand which might affect customers’ needs and expectations regarding products and services and SC performance, thereby causing overcosts and demanding greater effort from an organisation (Khan & Burnes, 2007).

 Interruption on any SC level can affect an enterprise in terms of product delivery, customer service and operation continuity (Juttner, Peck, & Christopher, 2003).

A study presented by Sanchez-Rodrigues & Naim (2010) observed that 60% of the most frequently occurring problems which can have the greatest effect on SC risk were related to delays, information availability, demand knowledge, delivery restrictions and SC coordination. Others having lesser effect on SC performance were related to infrastructure rigidity, operating costs, SC integration and technology.

SC risk is presented by internal and external or environmental factors including control, supply, demand and environmental risks (Christopher, 2005). Macro, safety, political, competitive and resource risks have been distinguished in similar classification (Manuj & Mentzer, 2008).

Supply risk

SC risk is defined as the probability of an incident associated with inbound supply from individual supplier failures or the supply mar-
ket occurring, in which its outcome results in purchasing firm inability to meet customer demand or causes threats to customers’ lives and safety (Zisdins, 2003). This kind of risk has implications throughout the SC affecting system productivity levels, inventory and cycle times (Eltantawy, Fox, & Giunipero, 2009).

The danger of shortages and interruptions jeopardise SC objectives, especially regarding product availability, quality conditions and total costs. Risk management action must thus be orientated towards understanding sources of supply regarding risk and state the best ways of managing this (Wu, Blackhurst, & Chidambaram, 2006).

Context and problems of risk regarding the oncological drug SC

It has been estimated that more than 12 million new cancer cases appear in the world each year (IARC/WHO, 2008), most (80%) appearing in developing countries (Ministerio de la Proteccion Social de la Republica de Colombia, 2010); 62,660 new cancer cases occurred in Colombia in 2008 (IARC/WHO, 2008). According to the last Basic Indicators for Monitoring Millenium Development Objectives report, Colombia’s mortality rate was 76.5 per 100,000 inhabitants; more than 34,000 people died in 2010 due to cancer (PAHO/MPS/INS, 2010).

Colombian pharmaceutical policy shows that some of the main problems in the Colombian health system are related to poor supply and availability of essential medicines. Regarding pharmaceutical policy, it was stated that only 63% of all insured people attended by the system and who were prescribed medicine (in 2008) received the complete formulation, 15.8% received it poorly and 21.2% did not received anything at all (Consejo Nacional de Politica Económica y Social – DNP, 2012).

Problems regarding medicine supply, availability and supply is a critical SC risk affecting Colombian patients and the population in general, due to public health, social and economic implications for the country.

A shortage of medicines affects the continuity of oncological treatment, thereby endangering patients’ health due to adjustments and changes in treatment schemes. At international level, it has been identified that oncological medicine shortages have forced treating physicians to set application priorities on patients and changes in treatment. For example, capecitabin may be substituted for 5-flourouracil in adjuvant therapy for colorectal cancer, although this kind of treatment option has not been proved regarding a cure for cancer (Chapner, 2011).

A shortage of medicines forces the search for substitutes thereby causing overcosts due to the difference in prices for available medicine on the market (United Nations, 2013).

A shortage of active agents has occurred in Colombia, such as 5-flourouracil, azatioprine, citarabín, chlorambucyl, doxorubicin, mercaptopurin, metotrexate and tioguanine. This situation has caused increased costs for the Colombian health system due to administrative weakening in contingency operations when searching for medicines on the market and purchasing decisions concerning trading agents having different levels of intermediation.

Research methodology

The study was focused on healthcare institutions (HCI) which are enabled to provide clinical oncology services (Diagnosis Support and Therapeutical Complementation Group code 709, according to the Checking Procedures for Conditions for Evaluating Oncological Services’ Handbook, Ministerio de Salud y Proteccion Social, 2012) identified from HCI special registration data (Ministerio de Salud y Proteccion Social, 2012).

Such HCI in Colombia providing clinical oncology services includes 217 hospitals and specialised clinical centres. A sample of 42 HCI was taken, according to the scope of data collection planning and programming pertinent resources. Sunter’s method was used for selecting the HCI, using proportional likelihood for sampling concerning HCI size and number of oncology patients attended (Särndal, Swensson, & Wretman, 1992).

Selecting drugs

Doxorrubicine’s active compounds were defined as study subject medicine in this research, considering Colombian Health and Social Protection Ministry information concerning such active principles which had a regular supply pattern during the past year, even though a shortage in the system was reported.

Doxorrubicine is used as chemotherapy medicine and is sold in two presentations: 10 mg and 50 mg vials. It is used for treating non-Hodgkin’s lymphoma, multiple myeloma (bone marrow cell cancer), acute leukaemia, Kaposi’s sarcoma, Ewing’s sarcoma, Wilm’s tumour and breast, suprarenal crust, endometrium, lung and ovarian cancer, in addition to cancer occurring in other parts of the body (American Cancer Society, 2011).

The SISMED (Ministerio de Salud y Proteccion Social, 2012) database, concerning units sold and prices, reported 229,573 units of doxorribucine being sold in Colombia during 2011.

Identifying, assessing and analysing risk

SC risk was identified, assessed and analysed using risk management methodology with a systemic focus, as appears in Figure 1. Three stages were considered: contextualisation, assessment and decision-making and feedback. Interaction between these stages led to dealing with the complete cycle of risk management where system performance is assessed as time elapses, allowing management action to be evaluated according to danger level and susceptibility to risk.

Figure 1. Risk management methodology

Stages 1 and 2 are dealt with in this research; stage 3 will be researched later on.

Risk relational theory was used for answering key theoretical and practical questions regarding the first stage concerning how and
why something is considered a risk. At least three conceptual elements concerning risk definition must be considered: an object, the damage and a link based on some kind of causality between the object and the damage (Boholm & Corvellec, 2011). The object becomes a risk factor causing a risk generator agent and can be an internal or external circumstance, natural phenomena or patterns within a social system.

Damage or risk consists of adverse circumstances which can be materialised and linkage is the systemic association between risk objects and objects at risk which can be stronger than others.

Four supply risks were identified concerning conceptualisation (stage 1, Figure 2): supply delay, disruption in supply, differences in quantities received and demand forecast errors. Such risks concerned a definition of internal and external risk factors; depleting a drug’s active compounds, affects pharmaceutical industry drug production due to scarcity of raw materials. Drug availability on the market depends on market supply and demand dynamics. Logistics system capacity is associated with response times and quality regarding drug management and delivery. There are also asymmetries of information which are a critical risk factor in SC links resulting from power relationships, competition conditions in the provider market, low coordination between SC agents and limited use of communication and information technologies.

Supply risk implications for the system were summarised into two effects: drug shortage in the SC and risk costs resulting from risk materialisation.

Risk assessment methodology was used in stage 2 (assessment), considering the likelihood of occurrence and risk impact. Likelihood and impact coreing scales were set, which allowed establishing risk areas: severe, major, medium and minor (Figure 3). It was found that disruption risks and delays in supply were rated severe and major; the risk of difference in received numbers was rated major and medium and error risk regarding forecasting demand was rated medium.

The expression presented by Liu, Xu, Li, Wang & Wu (2012) was used for quantifying the danger of risk:

\[
\text{Risk exposure} = P(\text{NO}) \times L(\text{NO})
\]

where:

- \(P(\text{NO})\) was the likelihood of a negative result, and
- \(L(\text{NO})\) was loss or effect due to the result.

System dynamics (SD) application

The system dynamics (SD) domain developed at the Massachusetts Institute of Technology (MIT) in 1950 by Jay Forrester is based on the structure and dynamics of complex systems. Control engineering and non-linear dynamic systems theory states that SD are used for developing formal models and simulation, leading to capturing complex dynamics for creating a favorable environment for learning and designing policy (Sterman, 2002).

![Figure 3. Risk evaluation](image)

Supply risk implications for the system were summarised into two effects: drug shortage in the SC and risk costs resulting from risk materialisation.

Risk assessment methodology was used in stage 2 (assessment), considering the likelihood of occurrence and risk impact. Likelihood and impact coreing scales were set, which allowed establishing risk areas: severe, major, medium and minor (Figure 3). It was found that disruption risks and delays in supply were rated severe and major; the risk of difference in received numbers was rated major and medium and error risk regarding forecasting demand was rated medium.

The expression presented by Liu, Xu, Li, Wang & Wu (2012) was used for quantifying the danger of risk:

\[
\text{Risk exposure} = P(\text{NO}) \times L(\text{NO})
\]

where:

- \(P(\text{NO})\) was the likelihood of a negative result, and
- \(L(\text{NO})\) was loss or effect due to the result.

System dynamics (SD) application

The system dynamics (SD) domain developed at the Massachusetts Institute of Technology (MIT) in 1950 by Jay Forrester is based on the structure and dynamics of complex systems. Control engineering and non-linear dynamic systems theory states that SD are used for developing formal models and simulation, leading to capturing complex dynamics for creating a favorable environment for learning and designing policy (Sterman, 2002).

![Figure 3. Risk evaluation](image)

Supply risk implications for the system were summarised into two effects: drug shortage in the SC and risk costs resulting from risk materialisation.

Risk assessment methodology was used in stage 2 (assessment), considering the likelihood of occurrence and risk impact. Likelihood and impact coreing scales were set, which allowed establishing risk areas: severe, major, medium and minor (Figure 3). It was found that disruption risks and delays in supply were rated severe and major; the risk of difference in received numbers was rated major and medium and error risk regarding forecasting demand was rated medium.

The expression presented by Liu, Xu, Li, Wang & Wu (2012) was used for quantifying the danger of risk:

\[
\text{Risk exposure} = P(\text{NO}) \times L(\text{NO})
\]

where:

- \(P(\text{NO})\) was the likelihood of a negative result, and
- \(L(\text{NO})\) was loss or effect due to the result.

System dynamics (SD) application

The system dynamics (SD) domain developed at the Massachusetts Institute of Technology (MIT) in 1950 by Jay Forrester is based on the structure and dynamics of complex systems. Control engineering and non-linear dynamic systems theory states that SD are used for developing formal models and simulation, leading to capturing complex dynamics for creating a favorable environment for learning and designing policy (Sterman, 2002).

![Figure 3. Risk evaluation](image)

Supply risk implications for the system were summarised into two effects: drug shortage in the SC and risk costs resulting from risk materialisation.

Risk assessment methodology was used in stage 2 (assessment), considering the likelihood of occurrence and risk impact. Likelihood and impact coreing scales were set, which allowed establishing risk areas: severe, major, medium and minor (Figure 3). It was found that disruption risks and delays in supply were rated severe and major; the risk of difference in received numbers was rated major and medium and error risk regarding forecasting demand was rated medium.

The expression presented by Liu, Xu, Li, Wang & Wu (2012) was used for quantifying the danger of risk:

\[
\text{Risk exposure} = P(\text{NO}) \times L(\text{NO})
\]

where:

- \(P(\text{NO})\) was the likelihood of a negative result, and
- \(L(\text{NO})\) was loss or effect due to the result.
DISP: outflow of drugs delivered by drugstore services (units/month)

EMCP: outflow of medicines sent to preparation centres (units/month)

Auxiliary variables:

SOTR: monthly value for added consumption of drugs in units/month

FCDE: correction factor for demand

AEPS: approval time for treatment by a healthcare service provider (EPS) (months)

PRTR: number of programmed treatments by HCI (units/month)

DEST: stock deficit is the difference regarding drug stock in a system regarding demand (units/month).

FRAI: risk factor regarding asymmetry of information

ORPR: number of drug units ordered by an EPS/HCI (units/month)

FRDM: suppliers’ market risk factor

FRPA: risk factor regarding availability of active compound

PROR: provider response to drug purchase order (units/month)

LTME: provider response time (units/month)

FRLS: logistics service risk factor

FEDI: percentage drugs delivered/supplied

FECP: percentage regarding sending drugs to preparation centres

COOR: ordering cost ($/month)

CUOR: ordering unit cost ($/month)

COMA: inventory maintenance cost ($/month)

CUMA: maintenance unit cost ($/unit)

CODI: distribution cost ($/unit)

CUDI: distribution unit cost ($/unit)

CORI: risk cost ($/month)

COPE: penalty cost ($/unit)

TCPE: penalty application time (month)

Model formulation

\[ SMED = \text{INTEG}(\text{ORRE} - \text{DISP} - \text{EMCP}, \text{SME}\text{D}_{(t-1)}) \]  
\[ \text{ORRE} = \text{fixed delay (PROR} \times (1 - \text{FRAI}), \text{LTME}, 0) \]  
\[ \text{DISP} = \text{if then else (PRTR} \geq \text{SMED}, \text{SMED} \times \text{FEDI}, \text{PRTR} \times \text{FEDI}) \]  
\[ \text{EMCP} = \text{if then else (PRTR} > \text{SMED}, \text{SMED} \times \text{FECP}, \text{PRTR} \times \text{FECP}) \]  
\[ \text{PRTR} = \text{fixed delay (SOTR} \times (1 + \text{FCDE}), \text{AEPS}, 0) \]  
\[ \text{DEST} = \text{if then else (PRTR} > \text{SMED}, \text{PRTR} - \text{SMED}, 0) \]  
\[ \text{ORPR} = \text{if then else (SMED} < \text{PRTR}, (\text{PRTR} - \text{SMED}) \times (1 - \text{FRAI}), 0) \]  
\[ \text{PROR} = \text{ORPR} \times (1 - \text{(FRPA + FRDM)}) \]  
\[ \text{COOP} = \text{CODI} + \text{COMA} + \text{COOR} + \text{CORI} \]  
\[ \text{CODI} = (\text{DISP} + \text{EMCP}) \times \text{CUDI} \]  
\[ \text{COMA} = \text{SMED} \times \text{CUMA} \]  
\[ \text{COOR} = \text{ORPR} \times \text{CUOR} \]  
\[ \text{CORI} = \text{fixed delay (DEST} \times \text{COPE}, \text{TCPE}), 0) \]  

Setting simulation and analysis runs

Two settings were assessed by using simulation runs during a 100-month period. The first setting included the risk factors evaluated in the study and their impact on system operation. The results of simulation in this setting (Figure 6) showed how entrance flow pattern was affected by risk factors, producing deficits during different periods due to differences between demand for and overall supply of drugs.
Table 1. Average and standard deviation for data produced by simulation

<table>
<thead>
<tr>
<th>Variable</th>
<th>Mean</th>
<th>Standard deviation</th>
</tr>
</thead>
<tbody>
<tr>
<td>PRT</td>
<td>19,183.47</td>
<td>2,740.22</td>
</tr>
<tr>
<td>AEPS</td>
<td>1.56</td>
<td>0.44</td>
</tr>
<tr>
<td>ORPR</td>
<td>12,661.54</td>
<td>2,076.09</td>
</tr>
<tr>
<td>PROR</td>
<td>7,206.38</td>
<td>1,370.55</td>
</tr>
<tr>
<td>ORRE</td>
<td>5,139.49</td>
<td>1,156.13</td>
</tr>
<tr>
<td>LTME</td>
<td>0.85</td>
<td>0.27</td>
</tr>
<tr>
<td>DEST</td>
<td>14,099.30</td>
<td>2,255.70</td>
</tr>
<tr>
<td>DISP</td>
<td>1,779.46</td>
<td>437.08</td>
</tr>
<tr>
<td>EMCP</td>
<td>3,304.71</td>
<td>811.72</td>
</tr>
</tbody>
</table>

The difference between stock level and treatment request in the system highlighted the problem of supply risk affecting SC. Outflow analysis led to observing system response during simulation time frames.

The cost pattern in the initial setting is presented in Figure 7 where the high penalty cost is reflected by the current condition of supply risk.

The second setting showing the hypothetical reduction of risk factors in supply was considered by applying risk mitigation and management strategies focused on policy definition and negotiation rules with market provider and agent coordination, where logistics service operators and statement, suitability of information systems for management and healthcare system regulating entities were included. This provided cross-support for the SC and provided reliable information for decision-making.

Such strategies will be defined in a subsequent stage of the study. However, projected values were taken on the basis of a research project hypothesis for assessing a mitigation setting. With this in mind, the simulation model was run with reduced risk factors for assessing the possible impact on system operation and associated costs. Figure 8 compares both settings.

Figure 9 shows operating cost pattern concerning a current setting and a theoretical setting.

Other more optimistic settings will enable better service and cost indicators. However, the hypothesis considers the complex market dynamics surpassing regulatory control and operation measures in current market conditions in Colombia.

Conclusions

The research has presented fundamental information about the effects of supply risk on the oncological drug supply chain in Colombia, the implications for operating costs and service level indicator, presupposing an effect on the health of cancer patients.

These results show that market response level was 56.91%, thereby implying a deficit in the medication system. Logistics service supply was 71.31%, representing delays in delivery times. It was found that waiting time for receiving treatment was longer than three months in 52% of cases. On average, it is known that only 38 out of every 100 patients requiring drugs will actually receive them in normal conditions.

Risk cost accounted for 70.66% of operating cases. According to the analysis, it was seen that the use of high cost drugs, substituting doxorubicine’s active compound, caused an increase in costs, thereby constituting the main system cost component.

The theoretical setting revealed that shortage occurring due to breaks in supply became reduced (obviously) where market response level would rise from 56.91% to 85.81%, meaning that cost could be reduced by 21.26% in this setting.

Future research

The results presented in the theoretical setting showed that additional research on defining SC risk management strategies were needed for reducing risk and affecting more critical environments, such as system economics and cancer patients’ health.

Acknowledgements

This work was financed by the Universidad Nacional de Colombia and Colciencias through a project framework called “A methodological approach for defining rules and policy for coordination and negotiation in the oncological medication supply chain in Colombia.”
References

Consejo Nacional de Política Económica y Social - DNP., Documento CONPES Social 155 - Política Farmacéutica Nacional., Colombia, August, 2012.